23andMe to Report Q2 FY2025 Financial Results
23andMe (Nasdaq: ME) announced it will report second quarter fiscal year 2025 financial results after market close on November 12, 2024. The company will host a conference call at 4:30 p.m. Eastern Time to discuss quarterly results and business progress. The event will be accessible via webcast, with a replay available afterward. Shareholders can submit and upvote questions through the Say Technologies platform up until 24 business hours before the earnings call.
23andMe (Nasdaq: ME) ha annunciato che riporterà i risultati finanziari del secondo trimestre dell'anno fiscale 2025 dopo la chiusura del mercato il 12 novembre 2024. L'azienda ospiterà una conferenza telefonica alle 16:30, ora orientale, per discutere i risultati trimestrali e i progressi aziendali. L'evento sarà accessibile tramite webcast, con una registrazione disponibile successivamente. Gli azionisti possono inviare e votare domande tramite la piattaforma Say Technologies fino a 24 ore lavorative prima della chiamata sugli utili.
23andMe (Nasdaq: ME) anunció que reportará los resultados financieros del segundo trimestre del año fiscal 2025 después del cierre del mercado el 12 de noviembre de 2024. La empresa llevará a cabo una conferencia telefónica a las 4:30 p.m., hora del Este, para discutir los resultados trimestrales y el progreso empresarial. El evento será accesible a través de un webcast, con una repetición disponible después. Los accionistas pueden enviar y votar preguntas a través de la plataforma Say Technologies hasta 24 horas hábiles antes de la llamada de ganancias.
23andMe (Nasdaq: ME)는 2025 회계연도 2분기 재무 결과를 2024년 11월 12일 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 동부 표준시 기준 오후 4시 30분에 분기 결과 및 사업 진행 상황에 대해 논의하기 위한 전화 회의를 개최할 것입니다. 이 이벤트는 웹캐스트를 통해 접근할 수 있으며, 이후 재생이 가능합니다. 주주들은 수익 발표 전화 회의 24시간 전까지 Say Technologies 플랫폼을 통해 질문을 제출하고 투표할 수 있습니다.
23andMe (Nasdaq: ME) a annoncé qu'il publiera les résultats financiers du deuxième trimestre de l'exercice fiscal 2025 après la clôture des marchés le 12 novembre 2024. L'entreprise tiendra une conférence téléphonique à 16h30, heure de l'Est, pour discuter des résultats trimestriels et des progrès des affaires. L'événement sera accessible par webcast, avec une rediffusion disponible par la suite. Les actionnaires peuvent soumettre et voter des questions via la plateforme Say Technologies jusqu'à 24 heures ouvrables avant la conférence de résultats.
23andMe (Nasdaq: ME) gab bekannt, dass die finanziellen Ergebnisse des zweiten Quartals des Geschäftsjahres 2025 nach Börsenschluss am 12. November 2024 veröffentlicht werden. Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Quartalsergebnisse und den Fortschritt des Unternehmens zu besprechen. Die Veranstaltung wird über einen Webcast zugänglich sein, mit einer Wiederholung, die anschließend verfügbar ist. Aktionäre können Fragen über die Say Technologies-Plattform bis zu 24 Arbeitsstunden vor dem Ergebnisgespräch einreichen und abstimmen.
- None.
- None.
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s results and report on business progress.
The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional shareholders to submit and upvote questions to management in advance of the earnings conference call. Shareholders can submit questions by visiting this link. The Q&A platform will remain open until 24 business hours before the earnings call.
About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, financial position, financial projections, funding for continued operations, cash reserves, projected costs, database growth, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
Contacts
Investor Relations Contact: investors@23andme.com
Media Contact: press@23andMe.com
FAQ
When will 23andMe (ME) release Q2 FY2025 earnings?
What time is 23andMe's (ME) Q2 FY2025 earnings call?
How can shareholders submit questions for 23andMe's (ME) Q2 earnings call?
